Home › Research › TREM2 and immune genetics
Secretases in Alzheimer's disease: Novel insights into proteolysis of APP and TREM2
Lichtenthaler SF, Tschirner SK, Steiner H.. Current opinion in neurobiology, 2021-10-22
Topic: Brain proteins, microglia and lab models
Plain-language summary
Secretases are a group of proteases that are major drug targets considered for the prevention and treatment of Alzheimer's disease (AD). Secretases do not only process the AD-linked neuronal amyloid precursor protein (APP) but also the triggering receptor expressed on myeloid cells 2 (TREM2), thereby controlling microglial functions. This review highlights selected recent discoveries for the α-secretases a disintegrin and metalloprotease 10 (ADAM10) and a disintegrin and metalloprotease 17 (ADAM17), the β-secretase β-site APP cleaving enzyme 1 (BACE1) and γ-secretase and their link to AD.
What this study adds
Evidence grade: Low
This is a narrative review. This review describes how secretases process both the amyloid precursor protein and TREM2, thereby controlling microglial functions, and notes that secretases are considered drug targets for Alzheimer's disease. It summarizes laboratory and genetic findings rather than reporting a proven treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lichtenthaler, S. F., Tschirner, S. K., & Steiner, H. (2022). Secretases in Alzheimer's disease: Novel insights into proteolysis of APP and TREM2. Current opinion in neurobiology. https://doi.org/10.1016/j.conb.2021.09.003
Vancouver
Lichtenthaler SF, Tschirner SK, Steiner H. Secretases in Alzheimer's disease: Novel insights into proteolysis of APP and TREM2. Current opinion in neurobiology. 2022. doi:10.1016/j.conb.2021.09.003. PMID: 34689040.
BibTeX
@article{lichtenthaler2022-34689040,
author = {Lichtenthaler, S. F. and Tschirner, S. K. and Steiner, H.},
title = {{Secretases in Alzheimer's disease: Novel insights into proteolysis of APP and TREM2}},
journal = {Current opinion in neurobiology},
year = {2022},
doi = {10.1016/j.conb.2021.09.003},
pmid = {34689040},
url = {https://doi.org/10.1016/j.conb.2021.09.003}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Secretases do not only process the AD-linked neuronal amyloid precursor protein (APP) but also the triggering receptor expressed on myeloid cells 2 (TREM2), thereby controlling microglial functions.
- This review highlights selected recent discoveries for the α-secretases a disintegrin and metalloprotease 10 (ADAM10) and a disintegrin and metalloprotease 17 (ADAM17), the β-secretase β-site APP cleaving enzyme 1 (BACE1) and γ-secretase and their link to AD.
- New genetic evidence strengthens the role of α-secretases in AD through cleavage of APP and TREM2.
- Novel proteins were linked to AD, which control α- and β-secretase activity through transcriptional and post-translational mechanisms.
Why it matters
This review describes how secretases process both the amyloid precursor protein and TREM2, thereby controlling microglial functions, and notes that secretases are considered drug targets for Alzheimer's disease. It summarizes laboratory and genetic findings rather than reporting a proven treatment or cure.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current opinion in neurobiology) |
| Journal's citation record | 3 / 4 | Current Opinion in Neurobiology: journal h-index 306 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 62 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.3 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 2 / 6 | Cited 1.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 37 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Harald Steiner: h-index 63 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Ludwig-Maximilians-Universität München: institution h-index 1,224 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34689040) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.conb.2021.09.003
- PubMed: 34689040
- Original source →
- Free full text: Current Opinion in Neurobiology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 34.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in TREM2 and immune genetics from nearby years
Also tagged “r47h”
363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.